Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size, Trends and Opportunities 2022-2030
- Category: Healthcare
- Published Date: May 2023
- Publisher: LP Information
- Pages: 90
Due to the COVID-19 pandemic, the global Glucagon Like Peptide-1 (GLP-1) Agonists Market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2022-2030. Fully considering the economic change by this health crisis, Less Than 95% accounting for % of the Glucagon Like Peptide-1 (GLP-1) Agonists global market in 2022, is projected to value US$ million by 2030, growing at a revised % CAGR from 2023 to 2030. While Fruits and Vegetables segment is altered to an % CAGR throughout this forecast period.
North America Glucagon Like Peptide-1 (GLP-1) Agonists market is estimated at US$ million in 2022, while Europe is forecast to reach US$ million by 2030. The proportion of the North America is % in 2021, while Europe percentage is %, and it is predicted that Europe share will reach % in 2030, trailing a CAGR of % through the analysis period 2023-2030. As for the Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Key segments including type and application have been elaborated in this report. The consultants at Intelligence Market Report have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows production and revenue data by type and application during the historical period (2019-2021) and forecast period (2023-2030).
Segment by Type
- Exenatied
- Liraglutide
- Lixisenatide
- Albiglutide
- Dulaglutide
Segment by Application
- Hospital
- Pharmacy
- Other
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and production data of each region and country for the period 2019-2030. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.
Production by Region
North America
Europe
China
Japan
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Competitive Scenario
In this section, the readers will gain an understanding of the key players competing. The experts at Intelligence Market Report have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and production by manufacturers for the period 2019-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Novo Nordisk
- AstraZeneca
- Eli Lily
- GSK
- Sanofi
- Bristol-Myers Squibb
- Amylin
1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview
1.1 Product Overview and Scope of Glucagon Like Peptide-1 (GLP-1) Agonists
1.2 Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Type
1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate Analysis by Type 2023 VS 203
1.2.2 Type 11.2.3 Type 2
1.3 Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Application
1.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Comparison by Application: 2023 VS 2030
1.3.2 Application 1
1.3.3 Application 2
1.3.4 Application 3
1.4 Global Market Growth Prospect
1.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Estimates and Forecasts (2019-2030)
1.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Production Capacity Estimates and Forecasts (2019-2030)
1.4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Production Estimates and Forecasts (2019-2030)
1.5 Global Market Size by Region
1.5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Estimates and Forecasts by Region: 2019 VS 2022 VS 2030
1.5.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Estimates and Forecasts (2019-2030)
1.5.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Estimates and Forecasts (2019-2030)
1.5.4 China Glucagon Like Peptide-1 (GLP-1) Agonists Estimates and Forecasts (2019-2030)
1.5.5 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Estimates and Forecasts (2019-2030)
2 Market Competition by Manufacturers
2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Production Capacity Market Share by Manufacturers (2019-2021)
2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Manufacturers (2019-2021)
2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Manufacturers (2019-2021)
2.5 Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Production Sites, Area Served, Product Type
2.6 Glucagon Like Peptide-1 (GLP-1) Agonists Market Competitive Situation and Trends
2.6.1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Concentration Rate
2.6.2 Global 5 and 10 Largest Glucagon Like Peptide-1 (GLP-1) Agonists Players Market Share by Revenue
2.6.3 Mergers & Acquisitions, Expansion
3 Production Capacity by Region
3.1 Global Production Capacity of Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Region (2019-2021)
3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2019-2021)
3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Production Capacity, Revenue, Price and Gross Margin (2019-2021)
3.4 North America Glucagon Like Peptide-1 (GLP-1) Agonists Production
3.4.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Production Growth Rate (2019-2021)
3.4.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Production Capacity, Revenue, Price and Gross Margin (2019-2021)
3.5 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Production
3.5.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Production Growth Rate (2019-2021
3.5.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Production Capacity, Revenue, Price and Gross Margin (2019-2021)
3.6 China Glucagon Like Peptide-1 (GLP-1) Agonists Production
3.6.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Production Growth Rate (2019-2021)
3.6.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Production Capacity, Revenue, Price and Gross Margin (2019-2021)
3.7 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Production
3.7.1 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Production Growth Rate (2019-2021)
3.7.2 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Production Capacity, Revenue, Price and Gross Margin (2019-2021)
4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Region
4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Region
4.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Region
4.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Market Share by Region
4.2 North America
4.2.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Country
4.2.2 United States
4.2.3 Canada
4.3 Europe
4.3.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Country
4.3.2 Germany
4.3.3 France
4.3.4 U.K.
4.3.5 Italy
4.3.6 Russia
4.4 Asia Pacific
4.4.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Region
4.4.2 China
4.4.3 Japan
4.4.4 South Korea
4.4.5 China Taiwan
4.4.6 Southeast Asia
4.4.7 India
4.4.8 Australia
4.5 Latin America
4.5.1 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Country
4.5.2 Mexico
4.5.3 Brazil
5 Segment by Type
5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Production Market Share by Type (2019-2021)
5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2021)
5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2019-2021)
6 Segment by Application
6.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Production Market Share by Application (2019-2021)
6.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2021)
6.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2019-2021)
7 Key Companies Profile
7.1 Company 1
7.1.1 Company 1 Glucagon Like Peptide-1 (GLP-1) Agonists Corporation Information
7.1.2 Company 1 Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
7.1.3 Company 1 Glucagon Like Peptide-1 (GLP-1) Agonists Production Capacity, Revenue, Price and Gross Margin (2019-2021)
7.1.4 Company 1 Main Business and Markets Served
7.1.5 Company 1 Recent Developments/Updates
7.2 Company 2
7.3 Company 3
7.4 Company 4
7.5 Company 5
7.6 Others
8 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Cost Analysis
8.1 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Glucagon Like Peptide-1 (GLP-1) Agonists
8.4 Glucagon Like Peptide-1 (GLP-1) Agonists Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List
9.3 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
10 Market Dynamics
10.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
10.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers
10.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
10.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints
11 Production and Supply Forecast
11.1 Global Forecasted Production of Glucagon Like Peptide-1 (GLP-1) Agonists by Region (2023-2030)
11.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Production, Revenue Forecast (2023-2030)
11.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Production, Revenue Forecast (2023-2030)
11.4 China Glucagon Like Peptide-1 (GLP-1) Agonists Production, Revenue Forecast (2023-2030)
11.5 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Production, Revenue Forecast (2023-2030)
12 Consumption and Demand Forecast
12.1 Global Forecasted Demand Analysis of Glucagon Like Peptide-1 (GLP-1) Agonists
12.2 North America Forecasted Consumption of Glucagon Like Peptide-1 (GLP-1) Agonists by Country
12.3 Europe Market Forecasted Consumption of Glucagon Like Peptide-1 (GLP-1) Agonists by Country
12.4 Asia Pacific Market Forecasted Consumption of Glucagon Like Peptide-1 (GLP-1) Agonists by Region
12.5 Latin America Forecasted Consumption of Glucagon Like Peptide-1 (GLP-1) Agonists by Country
13 Forecast by Type and by Application (2023-2030)
13.1 Global Production, Revenue and Price Forecast by Type (2023-2030)
13.1.1 Global Forecasted Production of Glucagon Like Peptide-1 (GLP-1) Agonists by Type (2023-2030)
13.1.2 Global Forecasted Revenue of Glucagon Like Peptide-1 (GLP-1) Agonists by Type (2023-2030)
13.1.3 Global Forecasted Price of Glucagon Like Peptide-1 (GLP-1) Agonists by Type (2023-2030)
13.2 Global Forecasted Consumption of Glucagon Like Peptide-1 (GLP-1) Agonists by Application (2023-2030)
13.2.1 Global Forecasted Production of Glucagon Like Peptide-1 (GLP-1) Agonists by Application (2023-2030)
13.2.2 Global Forecasted Revenue of Glucagon Like Peptide-1 (GLP-1) Agonists by Application (2023-2030)
13.2.3 Global Forecasted Price of Glucagon Like Peptide-1 (GLP-1) Agonists by Application (2023-2030)
14 Research Finding and Conclusion
15 Methodology and Data Source
15.1 Methodology/Research Approach
15.1.1 Research Programs/Design
15.1.2 Market Size Estimation
15.1.3 Market Breakdown and Data Triangulation
15.2 Data Source
15.2.1 Secondary Sources
15.2.2 Primary Sources
15.3 Author List
15.4 Disclaimer